Safety and Efficacy of Radio Frequency for the Treatment of Mild to Severe Inflammatory Acne

Clinical Evaluation of Safety and Efficacy of the InMode RF Pro System With the Morpheus8 Applicator for the Treatment of Mild to Severe Inflammatory Acne Vulgaris

The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris

Study Overview

• Status: Active, not recruiting
• Conditions: Inflammatory Acne Vulgaris
• Intervention / Treatment: Device: Morpheus8 Applicator Radiofrequency device

Detailed Description

The aim of this trial is to evaluate the safety and efficacy of the InMode RF Pro System with the Morpheus8 face tip (24 pins) applicator for the treatment of mild, moderate and severe, facial acne vulgaris. Prospective, multicenter clinical study

• Study Type: Interventional
• Enrollment (Estimated): 42
• Phase: Not Applicable

Contacts and Locations

• Study Contact: Name: Meital Matalon, MS; Phone Number: 324 9492588870; Email: meital.matalon@inmodemd.com
• Study Contact Backup: Name: Maria Shusterman, RN; Phone Number: 317 9492396522; Email: maria.shusterman@inmodemd.com

Study Locations

• United States
  • Arizona
    • Oro Valley, Arizona, United States, 85704
      • Avant Dermatology Aesthetics
  • Colorado
    • Greenwood Village, Colorado, United States, 80111
      • AboutSkin Research, LLC
      • Contact: Deborah Dahler; Phone Number: 114 303-756-7546; Email: ddahler@aboutskinderm.com
  • New York
    • New York, New York, United States, 10003
      • UnionDerm
      • Contact: Ellie Smeallie, MD; Phone Number: 212-366-5400; Email: research@unionderm.com
  • Texas
    • Dallas, Texas, United States, 75390
      • UT Southwestern Medical Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: Child; Adult; Older Adult
• Accepts Healthy Volunteers: Yes

Description

Inclusion Criteria:

• Subject is >16 years of age
• General good health confirmed by medical history and examination of the treated area.
• Subjects with mild to severe Acne Vulgaris, defined as a baseline IGA (Investigator's Global Assessment) score of 2, 3 or 4 and 10-100 inflammatory lesions (papules or pustules).
• The patients should be willing to comply with the study procedure and schedule, including the follow up visits, and will refrain from using any other acne treatment methods during the entire study period.
• Willing to avoid sun/UV exposure for duration of the study unless using sunscreen.
• Willing to refrain from starting or changing hormonal contraception for duration of study.
• Subject understands and is willing to sign the informed consent to participate in the study. Parental (or other) guardians must provide consent for minors under the age of 18.

Exclusion Criteria:- Pacemaker or internal defibrillator, or any other active electrical implant anywhere in the body.

• Patients who are under pharmacological anti-acne therapy (isotretinoin or antibiotics) for the last 6 months.
• Use of botulinum toxin within prior 1 month.
• Permanent implant in the treated area such as metal plates and screws, silicone implants or an injected chemical substance
• Current or history of cancer, or premalignant condition in the treatment area.
• Severe concurrent conditions, such as cardiac disorders, epilepsy, uncontrolled hypertension, and liver or kidney diseases.
• Subject who are pregnant or nursing.
• Started or changed hormonal contraceptive within prior month of study.
• Subject is unwilling or unlikely to refrain from high UV exposure to face.
• Impaired immune system due to immunosuppressive diseases such as AIDS and HIV, or use of immunosuppressive medications.
• Patients with history of diseases stimulated by heat, such as recurrent Herpes Simplex in the treatment area
• Poorly controlled endocrine disorders, such as diabetes or thyroid dysfunction.
• Any active condition in the treatment area, such as sores, psoriasis, eczema, and rash.
• History of skin disorders, keloids, abnormal wound healing, as well as very dry and fragile skin.
• History of bleeding coagulopathies or use of anticoagulants in the last 10 days.
• Any surgery in treated area within 3 months prior to treatment.
• Subject received other treatments such as light, CO2 laser or RF in the treatment area within 6 months of study start date.
• Simultaneous participation in another investigator drug or device study or completion of the follow-up phase for the primary endpoint of any previous study less than 30 days prior to the first evaluation in this study.
• Subject that has any condition that, at the investigator's discretion, renders the subject unsuitable for participation in this clinical research study.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: N/A
• Interventional Model: Single Group Assignment
• Masking: None (Open Label)

Number of Arms

1

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Experimental: Device treatment; Treatment area will include affected areas over the entire face (presence of comedones, pustules, papules, nodules and cysts	Device: Morpheus8 Applicator Radiofrequency device; Eligible subjects will receive 2 treatments with the Morpheus8 according to the study protocol. All participants will return for 2 follow up visits: 4 weeks (1M FU) and 12 weeks (3M FU) after the 2nd treatment. Total expected study duration is ~6 months, depending on subject recruitment rate.

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Percent of responder	Percent of responders, where responders are defined as subjects with at least a 50% reduction in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs. Success Criteria: Success will be achieved if at least 50% of enrolled subjects are responders.	Month 3

Secondary Outcome Measures

Outcome Measure	Measure Description	Time Frame
Absolute change in number of inflammatory acne lesions	Absolute change in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs	Month 3
Percentage of subjects with a ≥2 point score improvement on the Investigators Global Assessment (IGA) scale	Percentage of subjects with a ≥2 point score improvement on the Investigators Global Assessment (IGA) scale at 12 weeks after the last treatment compared to baseline as assessed by three independent reviewers using clinical photographs.	Month 3
Absolute change in non-inflammatory acne lesions	Absolute change In non-inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers from clinical photographs	Month 3
The rate of patient satisfaction with treatment,	The rate of patient satisfaction with treatment, using a 5-point Likert scale at 12 weeks after the last treatment	Month 3
percent change in non-inflammatory acne lesions	percent change in number of inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers using clinical photographs	Month 3
Percent change in non-inflammatory acne lesions	Percent change in non-inflammatory acne lesions from baseline to 12 weeks after the last treatment, as assessed by 3 independent reviewers from clinical photographs	Month 3

Collaborators and Investigators

• Sponsor: InMode MD Ltd.
• Investigators: Principal Investigator: Anna M Chapas, MD; Principal Investigator: Jole L Cohen, MD, Unafilliated

Study record dates

Study Major Dates

• Study Start (Actual): May 1, 2023
• Primary Completion (Estimated): May 1, 2025
• Study Completion (Estimated): May 1, 2026

Study Registration Dates

• First Submitted: April 13, 2023
• First Submitted That Met QC Criteria: April 25, 2023
• First Posted (Actual): April 26, 2023

Study Record Updates

• Last Update Posted (Actual): March 1, 2024
• Last Update Submitted That Met QC Criteria: February 29, 2024
• Last Verified: February 1, 2024

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Skin Diseases; Acneiform Eruptions; Sebaceous Gland Diseases; Acne Vulgaris
• Other Study ID Numbers: DO611175A

Plan for Individual participant data (IPD)

• Plan to Share Individual Participant Data (IPD)?: NO

Drug and device information, study documents

• Studies a U.S. FDA-regulated drug product: No
• Studies a U.S. FDA-regulated device product: Yes
• product manufactured in and exported from the U.S.: No